Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantBG
Baillie Gifford
Activity from announced rounds
Activity in this selectionBiotech
Baillie Gifford is an investment partnership with a private-growth investing business, backing companies before public listing within a broader long-term equity investment platform.
Its private-growth team looks for companies with a proven product and fast-growing revenue, across sectors and countries. It concentrates on a selected group of businesses with the potential to become major global enterprises.
Public-market mandates can remain invested after an IPO. That structure lets the partnership continue owning a business through listing, rather than requiring the private financing relationship to end at that milestone.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.1B 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionChai Discovery
Building AI models to accelerate pre-clinical drug discovery
$400MSeries C
Role not disclosedLoyal
Loyal develops medicines intended to extend dogs’ lifespans.
$100MSeries C
Role not disclosedCellares
Develops automated cell therapy manufacturing platforms
$257MSeries D
Role not disclosed